Natural elements can pose a threat to furniture items stored in a storage units. Extreme temperatures, whether high or low, can wear leather or wooden items. Storage units are meant to keep items safe and unharmed. To yield maximum protection, renting a climate controlled unit is a primary option. These units will produce benefits that non-regulated units cannot guarantee.

Climate controlled storage units offer weathering protection, are cost effective, more secure, and comfortable to visit.

Temperature controlled units are typically maintained at 55 and 85 degrees Farenheit. This protects against humidity and freezing effects. If the unit is in a very warm environment, humidity can set in. Moisuture in the air can then change the furniture. Freezing can cause wood to expand and contract, which results in the furniture weakening or even cracking. Extreme heat or cold can yellow any item, and overall leave them with a tampered look.

While climate controlled units are more expensive, they can be cost effective in the long run. If weathering effects have ruined your items, it can be more expensive to replace them in comparison to purchasing a controlled unit in the first place. Because of this, valuable items should be stored in temperature controlled units. Placement of valuables in these units also gives them a higher level of security. No one should suffer the loss of a prized possession with so many options available. Typically, temperature controlled units are in the middle of a facility. Unlike drive-up units, they are away from every-day commotion.

Lastly, climate controlled storage units are more comfortable to visit for two reasons: the room temperature and cleanliness of the unit. If you are going to be frequenting the unit, you don’t want to spend time in a confined room at 95 degrees. Controlled units provide a place for owners to spend time in the units. Furthermore, they are cleaner. Less debris can reach the interior as compared to those on the edge of the facility.

Placing items in a climate controlled unit is prosperous in the long run, and is worth every mover to consider.

read more

Acute coronary syndrome is simply a blanket term that encompasses cardiac incidents in which blood flow to the heart is disturbed. This could include a heart attack, unstable angina, or simply mean clotting in the arteries. Many of these episodes are fatal or can cause permanent damage to the heart.

Chest pain is the main warning sign associated with acute coronary syndrome. Other common signs of heart problems include discomfort in the limbs, shortness of breath, dizziness, nausea, or sweating. The symptoms may come and go, be sudden, or cause continuous pain.

Xarelto, an anticoagulant manufactured by Johnson & Johnson and Bayer, was prescribed to treat acute coronary syndrome to prevent blood clots from forming. However, according to the website of the attorneys at Williams Kherkher, Xarelto may not be a viable option to treating acute coronary syndrome due to the serious side effects that it is reported to cause. While the drug is still prescribed for short-term use in acute coronary syndrome cases in the United Kingdom, the U.S. Food and Drug Administration advisory committee have consistently denied the approval of Xarelto for that purpose.

A trial to test rivaroxaban in acute coronary syndrome cases took place to challenge the FDA’s ruling against the use of Xarelto. ATLAS ACS 2-TIMI 51 tested the effectiveness of very-low doses of Xarelto at 2.5 mg twice daily in trial patients. It was found that the drug reduced the risk for cardiovascular related death in reference to the placebo. However, the excess risk of bleeding was also found in users of the drug.

Over the course of 31 months, 15,526 patients with a recent episode of cardiovascular problems were given the placebo, 2.5 mg, or 5 mg of rivaroxaban. At the end of the trial, the instances of cardiovascular death, heart failure, and stroke. The treatment worked best with young, healthier patients rather than the predominant older population suffering from cardiovascular health concerns that were more likely to experience bleeding incidents. The FDA is currently investigating Xarelto for its increased risk of serious bleeding incidents.

read more